| 1. |
Pawlik TM, Raut CP, Rodriguez-Bigas MA. Colorectal carcinogenesis: MSI-H versus MSI-L. Dis Markers, 2004, 20(4-5): 199-206.
|
| 2. |
Wang HL, Kim CJ, Koo J, et al. Practical immunohisto-chemistry in neoplastic pathology of the gastrointestinal tract, liver, biliary tract, and pancreas. Arch Pathol Lab Med, 2017, 141(9): 1155-1180.
|
| 3. |
高顯華, 張衛, 白辰光. 免疫組化篩查林奇綜合征的缺陷和應對策略. 中華結直腸疾病電子雜志, 2019, 8(5): 439-446.
|
| 4. |
Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature, 2012, 487(7407): 330-337.
|
| 5. |
Kopetz S, Mcdonough SL, Morris VK, et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). J Clin Oncol, 2017, 35(4 Suppl): 520-520.
|
| 6. |
Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol, 2017, 30(9): 1299-1311.
|
| 7. |
Romiti A, Roberto M, Marchetti P, et al. Study of histopathologic parameters to define the prognosis of stage Ⅱ colon cancer. Int J Colorectal Dis, 2019, 34(5): 905-913.
|
| 8. |
Lee VWK, Chan KF. Tumor budding and poorly-differentiated cluster in prognostication in Stage Ⅱ colon cancer. Pathol Res Pract, 2018, 214(3): 402-407.
|
| 9. |
Costas-Chavarri A, Nandakumar G, Temin S, et al. Treatment of patients with early-stage colorectal cancer: ASCO Resource-Stratified Guideline. J Glob Oncol, 2019, 5: 1-19.
|
| 10. |
Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol, 2016, 17(6): 738-746.
|
| 11. |
Cenaj O, Ligon AH, Hornick JL, et al. Detection of ERBB2 amplification by next-generation sequencing predicts HER2 expression in colorectal carcinoma. Am J Clin Pathol, 2019, 152(1): 97-108.
|
| 12. |
Solomon JP, Hechtman JF. Detection of NTRK fusions: merits and limitations of current diagnostic platforms. Cancer Res, 2019, 79(13): 3163-3168.
|
| 13. |
Kim S, Fran?ois E, André T, et al. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Lancet Oncol, 2018, 19(8): 1094-1106.
|
| 14. |
Matsunaga M, Miwa K, Oka Y, et al. Successful treatment of metastatic anal canal adenocarcinoma with mFOLFOX6 + Bevacizumab. Case Rep Oncol, 2016, 9(1): 249-254.
|
| 15. |
Rao S, Sclafani F, Eng C, et al. InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment na?ve disease - An International Rare Cancers Initiative (IRCI) trial. 2018 ESMO, Munich, Germany, 2018-10-22, Abstract LBA21.
|
| 16. |
Ott PA, Piha-Paul SA, Munster P, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol, 2017, 28(5): 1036-1041.
|
1/5
WeChat